Randomized, double-blind comparison of ceftazidime and moxalactam in complicated urinary tract infections. 1985

E A Horowitz, and L C Preheim, and T J Safranek, and M P Pugsley, and C C Sanders, and M J Bittner

Sixty-seven patients with complicated urinary tract infections were randomized in double-blind fashion to ceftazidime or moxalactam (MOX). A total of 54 patients were evaluable, 27 in each group. Patients received 500 mg of antibiotic intravenously every 12 h, except for those with Pseudomonas aeruginosa randomized to MOX who received 2 g intravenously every 12 h. Toxic effects with ceftazidime were experienced by the following number of patients: pain with infusion, one; posttherapy diarrhea, one; liver function test elevations, two; and neutropenia, one. Toxic effects with MOX were experienced by the following number of patients: liver function test elevations, two; and prolonged prothrombin time, one. All resolved. At 1 week posttherapy, bacteriologic results were 74% cured, 11% relapsed, 15% reinfection with ceftazidime and 52% cured, 33% relapsed, and 19% reinfection with MOX. Ceftazidime was effective for infections caused by MOX-resistant P. aeruginosa. P. aeruginosa resistant to MOX and other beta-lactams was isolated from one patient after MOX therapy. Enterococcal reinfection was common in both groups.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009070 Moxalactam Broad- spectrum beta-lactam antibiotic similar in structure to the CEPHALOSPORINS except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain CEPHALOSPORINS. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections. 1-Oxacephalosporin,6059-S,Disodium Latamoxef,Disodium Moxalactam,Festamoxin,Lamoxactam,Latamoxef,Lilly 127935,Ly-127935,Ly127935,Moxalactam Disodium,S-6059,Shiomarin,1 Oxacephalosporin,6059 S,6059S,Disodium, Moxalactam,Latamoxef, Disodium,Ly 127935,Moxalactam, Disodium,S 6059,S6059
D002442 Ceftazidime Semisynthetic, broad-spectrum antibacterial derived from CEPHALORIDINE and used especially for Pseudomonas and other gram-negative infections in debilitated patients. Ceftazidime Anhydrous,Ceftazidime Pentahydrate,Fortaz,Fortum,GR-20263,LY-139381,Pyridinium, 1-((7-(((2-amino-4-thiazolyl)((1-carboxy-1-methylethoxy)imino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt, pentahydrate, (6R-(6alpha,7beta(Z)))-,Tazidime,GR 20263,GR20263,LY 139381,LY139381
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D014552 Urinary Tract Infections Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA. Infection, Urinary Tract,Infections, Urinary Tract,Tract Infection, Urinary,Tract Infections, Urinary,Urinary Tract Infection

Related Publications

E A Horowitz, and L C Preheim, and T J Safranek, and M P Pugsley, and C C Sanders, and M J Bittner
April 1983, The American journal of medicine,
E A Horowitz, and L C Preheim, and T J Safranek, and M P Pugsley, and C C Sanders, and M J Bittner
September 1988, Antimicrobial agents and chemotherapy,
E A Horowitz, and L C Preheim, and T J Safranek, and M P Pugsley, and C C Sanders, and M J Bittner
October 1983, Antimicrobial agents and chemotherapy,
E A Horowitz, and L C Preheim, and T J Safranek, and M P Pugsley, and C C Sanders, and M J Bittner
January 1982, Reviews of infectious diseases,
E A Horowitz, and L C Preheim, and T J Safranek, and M P Pugsley, and C C Sanders, and M J Bittner
January 1980, Clinical therapeutics,
E A Horowitz, and L C Preheim, and T J Safranek, and M P Pugsley, and C C Sanders, and M J Bittner
July 1983, The Journal of antimicrobial chemotherapy,
E A Horowitz, and L C Preheim, and T J Safranek, and M P Pugsley, and C C Sanders, and M J Bittner
March 1993, The American journal of medicine,
E A Horowitz, and L C Preheim, and T J Safranek, and M P Pugsley, and C C Sanders, and M J Bittner
March 1999, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi,
E A Horowitz, and L C Preheim, and T J Safranek, and M P Pugsley, and C C Sanders, and M J Bittner
April 1991, Hinyokika kiyo. Acta urologica Japonica,
E A Horowitz, and L C Preheim, and T J Safranek, and M P Pugsley, and C C Sanders, and M J Bittner
July 1983, The Journal of antimicrobial chemotherapy,
Copied contents to your clipboard!